Early bird registration is open and closes May 2025. Register now

AstraZeneca in Respiratory & Immunology

Respiratory & Immunology, part of AstraZeneca BioPharmaceuticals is a key disease area and growth driver to the Company.

AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases. The Company is committed to addressing the vast unmet needs of these chronic, often debilitating, diseases with a pipeline and portfolio of inhaled medicines, biologics and new modalities aimed at previously unreachable biologic targets. Our ambition is to deliver life-changing medicines that help eliminate COPD as a leading cause of death, eliminate asthma attacks and achieve clinical remission in immune-mediated diseases.

Share This Partner / Exhibitor

Key dates

Registrations
Abstracts

More Partners / Exhibitors

LG Chem

Boehringer Ingelheim

UCB

Celltrion

Celltrion

Meeting Place Fukuoka

FCVB

EMJ Rheum

EMJ